The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
By adopting this framework, dosing optimization can be approached to provide support for the rational design of piperacillin/tazobactam dosing regimens and other β-lactam/β-lactamase combinations. The shift from the conventional MIC to a β-lactamase inhibitor concentration-dependent metric clearly improved the knowledge of the susceptibility of a pathogen against piperacillin/tazobactam.
Authors
- Ferdinand Weinelt (ORCID: https://orcid.org/0000-0003-3024-3890)
- Wilhelm Huisinga (ORCID: https://orcid.org/0000-0002-5249-3914)
- Michael Zöller (ORCID: https://orcid.org/0000-0002-5337-6509)
- Johannes Zander (ORCID: https://orcid.org/0000-0003-4539-0703)
- Malin Andersson (ORCID: https://orcid.org/0009-0005-2418-9500)
- Robin Michelet (ORCID: https://orcid.org/0000-0002-5485-607X)
- Charlotte Kloft (ORCID: https://orcid.org/0000-0001-9344-8514)
- Jette Jung (ORCID: https://orcid.org/0000-0002-0111-809X)
- Franz Weber (ORCID: https://orcid.org/0009-0002-4654-7434)
- Nicole Zimmermann (ORCID: https://orcid.org/0009-0002-3157-814X)
Institutions
- University of Potsdam (DE)
- University of Konstanz (DE)
- Klinikum Konstanz (DE)
- Freie Universität Berlin (DE)
- Ludwig-Maximilians-Universität München (DE)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1093/jac/dkaf406
- Citations
- 1
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 1.39